Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.08 USD

103.08
763,344

+0.13 (0.13%)

Updated Aug 7, 2025 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Zacks Equity Research

Should You Continue to Hold Veracyte Stock in Your Portfolio?

by Zacks Equity Research

Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.

Zacks Equity Research

Reasons to Hold TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.

Zacks Equity Research

PAHC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Is it the Right Time to Hold STERIS Stock in Your Portfolio?

by Zacks Equity Research

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Zacks Equity Research

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Zacks Equity Research

Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $93.67, marking a +1.11% move from the previous day.

Zacks Equity Research

DGX Stock Gains Following the Launch of New AD-Detect Blood Test

by Zacks Equity Research

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.

Zacks Equity Research

Boston Scientific (BSX) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Boston Scientific (BSX) Surges 6.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Boston Scientific (BSX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Should You Continue to Hold NVST Stock in Your Portfolio?

by Zacks Equity Research

Investors are optimistic about Envista, thanks to its strong momentum in the Specialty Products and Technologies segment.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL continues to witness growth on the back of its strong product portfolio.

Zacks Equity Research

Is it the Right Time to Retain Labcorp Stock in Your Portfolio?

by Zacks Equity Research

LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus.

Zacks Equity Research

Is it the Right Time to Add EYE Stock to Your Portfolio Now?

by Zacks Equity Research

National Vision continues to draw investors' attention with its strategic transformation efforts. Positive industry trends should also favor its growth.

Zacks Equity Research

ICUI Stock Gains Following Latest FDA Approvals for Precision IV Pumps

by Zacks Equity Research

ICU Medical aims to enable healthcare systems to customize infusion setups, optimizing device footprint without compromising performance or safety.

Zacks Equity Research

GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform

by Zacks Equity Research

GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.

Zacks Equity Research

PODD Stock Benefits From the Launch of Omnipod 5 in Canada

by Zacks Equity Research

Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.

Zacks Equity Research

Reasons to Retain Penumbra Stock in Your Portfolio for Now

by Zacks Equity Research

PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.

Zacks Equity Research

Bruker Announces Groundbreaking 1.3 GHz NMR System, Stock Up

by Zacks Equity Research

BRKR's new 1.3 GHz high-resolution NMR system comes with a stable, standard-bore 54 mm superconducting magnet.

Zacks Equity Research

BD Seeks Potential Buyers for Life Sciences Business Division

by Zacks Equity Research

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Zacks Equity Research

ZBH Stock to Gain From Volume Growth Amid Rising Costs

by Zacks Equity Research

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Zacks Equity Research

GMED Stock May Benefit Following the Acquisition of Nevro

by Zacks Equity Research

Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.

Zacks Equity Research

Reasons to Add Fresenius Medical Stock to Your Portfolio Now

by Zacks Equity Research

FMS continues to gain traction on the back acquisitions & partnerships. A tough regulatory environment raises concerns.